Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens

Gerald A. Denys, Chris M. Pillar, Daniel F. Sahm, Peter O'Hanley, Jackson T. Stephens

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from<0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

Original languageEnglish (US)
Pages (from-to)4911-4914
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number8
DOIs
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens'. Together they form a unique fingerprint.

  • Cite this